Navigation Links
Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium
Date:12/10/2007

Scientific Presentations Detail Progress with VeraTag(TM) Assays in Breast

Cancer

SOUTH SAN FRANCISCO, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced five posters to be presented at the 30th San Antonio Breast Cancer Symposium taking place in San Antonio, TX, from December 13 - 16, 2007. Following are details for each embargoed session:

-- Friday, December 14th, 2007, 7.00 am - 9.00 am CST

Abstract # 2007: Quantitative measurements of HER2 expression and

HER2:HER2 dimerization identify subgroups of HER2 positive metastatic

breast cancer patients with different probabilities of response to

trastuzumab treatment. (Presenter: W. Huang)

-- Friday, December 14th, 2007, 7.00 am - 9.00 am CST

Abstract # 2011: Development of novel proximity-based immunoassays for

the detection of HER heterodimerization in breast cancer cell line

lysates and formalin-fixed, paraffin-embedded tissue.

(Presenter: L. Eli)

-- Friday, December 14th, 2007, 7.00 am - 9.00 am CST

Abstract # 2012: Characterization of a novel proximity immunoassay for

the quantitative determination of HER2 protein expression and HER2

homodimerization in formalin-fixed, paraffin-embedded breast cancer

tissue. (Presenter: J. Winslow)

-- Saturday, December 15th, 2007, 7.00 am - 9.00 am CST

Abstract # 4108: Profiling HER-family receptor dimerization in HER2

over expressing cells that co-express mutated EGFR receptors.

(Presenter: R. Dua)

-- Saturday, December 15th, 2007, 5.00 pm - 7.00 pm CST

Abstract # 5002: Increased detection of breast cancer markers human

epidermal growth factor receptor dimer and downstream signaling

proteins utilizing the VeraTag technology with dextran modified

antibodies. (Presenter: J. Wallweber)

About HERmark(TM)

HERmark is a propriety diagnostic that accurately quantifies HER2 expression and dimerization in patients with breast cancer. Preliminary data from three cohorts of trastuzumab-treated patients with metastatic breast cancer who were identified as "HER2 positive" by conventional assays suggest that HERMark can identify patients who are likely to respond to Herceptin with greater precision than currently available tests, permitting stratification of patients according to their degree of clinical benefit from the drug. Additional studies of HERmark for breast cancer in both the metastatic and adjuvant settings are in progress.

About VeraTag(TM)

VeraTag is a proximity-based assay technology platform that accurately quantifies proteins and functional protein complexes. This platform provides a researcher or clinician a more thorough understanding of protein-protein interactions or signaling pathway activity allowing for disease characterization at the molecular level. VeraTag is designed to run on standard formalin-fixed paraffin embedded (FFPE) patient samples.

About Monogram

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

VeraTag and HERmark are trademarks of Monogram Biosciences, Inc.

Contacts: Alfred G. Merriweather Jeremiah Hall

Chief Financial Officer Feinstein Kean Healthcare

Tel: 650 624 4576 Tel: 415 677 2700

amerriweather@monogrambio.com jeremiah.hall@fkhealth.com


'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
2. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
(Date:9/19/2017)... 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, ... three leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis ... global supply chains, has published the first annual edition of its Global ... more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that ... ... Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
Breaking Medicine News(10 mins):